FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2346104295> ?p ?o ?g. }

• W2346104295 endingPage "600" @default.
• W2346104295 startingPage "589" @default.
• W2346104295 abstract "[V4Q5]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V4Q5]dDAVP inhibits angiogenesis and metastatic progression of the disease without overt toxicity. Despite chemotherapy remaining as a primary therapeutic option for aggressive breast cancer, its use is limited by low selectivity and associated adverse effects. In this regard, we evaluated potential combinational benefits by adding [V4Q5]dDAVP to standard-of-care chemotherapy. In vitro, combination of [V4Q5]dDAVP with sub-IC50 concentrations of paclitaxel or carmustine resulted in a cooperative inhibition of breast cancer cell growth in comparison to single-agent therapy. In vivo antitumour efficacy of [V4Q5]dDAVP addition to chemotherapy was first evaluated using the triple-negative MDA-MB-231 breast cancer xenograft model. Tumour-bearing mice were treated with i.v. injections of [V4Q5]dDAVP (0.3 μg/kg, thrice weekly) in combination with weekly cycles of paclitaxel (10 mg/kg i.p.). After 6 weeks of treatment, combination regimen resulted in greater tumour growth inhibition compared to monotherapy. [V4Q5]dDAVP addition was also associated with reduction of local aggressiveness, and impairment of tumour invasion and infiltration of the skin. Benefits of combined therapy were confirmed in the hormone-independent and metastatic F3II breast cancer model by combining [V4Q5]dDAVP with carmustine (25 mg/kg i.p.). Interestingly, [V4Q5]dDAVP plus cytotoxic agents severely impaired colony forming ability of tumour cells and inhibited breast cancer metastasis to lung. The present study shows that [V4Q5]dDAVP may complement conventional chemotherapy by modulating metastatic progression and early stages of microtumour establishment, and thus supports further preclinical testing of the compound for the management of aggressive breast cancer." @default.
• W2346104295 created "2016-06-24" @default.
• W2346104295 creator A5016915382 @default.
• W2346104295 creator A5033272451 @default.
• W2346104295 creator A5060968852 @default.
• W2346104295 creator A5079339358 @default.
• W2346104295 creator A5087962688 @default.
• W2346104295 creator A5091444297 @default.
• W2346104295 date "2016-05-05" @default.
• W2346104295 modified "2023-10-16" @default.
• W2346104295 title "Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models" @default.
• W2346104295 cites W1523553171 @default.
• W2346104295 cites W1570858614 @default.
• W2346104295 cites W1750814356 @default.
• W2346104295 cites W1757407923 @default.
• W2346104295 cites W1864811189 @default.
• W2346104295 cites W1865619950 @default.
• W2346104295 cites W1967619145 @default.
• W2346104295 cites W1985298211 @default.
• W2346104295 cites W1985682422 @default.
• W2346104295 cites W1986737744 @default.
• W2346104295 cites W1987337616 @default.
• W2346104295 cites W1989505648 @default.
• W2346104295 cites W1991008524 @default.
• W2346104295 cites W1994930469 @default.
• W2346104295 cites W2010663401 @default.
• W2346104295 cites W2019828347 @default.
• W2346104295 cites W2021447985 @default.
• W2346104295 cites W2027706343 @default.
• W2346104295 cites W2033130032 @default.
• W2346104295 cites W2034524798 @default.
• W2346104295 cites W2043328703 @default.
• W2346104295 cites W2047318979 @default.
• W2346104295 cites W2052753575 @default.
• W2346104295 cites W2053572688 @default.
• W2346104295 cites W2066589515 @default.
• W2346104295 cites W2067314563 @default.
• W2346104295 cites W2067921628 @default.
• W2346104295 cites W2077340768 @default.
• W2346104295 cites W2079836135 @default.
• W2346104295 cites W2085819888 @default.
• W2346104295 cites W2086971118 @default.
• W2346104295 cites W2088835441 @default.
• W2346104295 cites W2090453278 @default.
• W2346104295 cites W2096745115 @default.
• W2346104295 cites W2097022339 @default.
• W2346104295 cites W2097887789 @default.
• W2346104295 cites W2100388022 @default.
• W2346104295 cites W2104422240 @default.
• W2346104295 cites W2106292881 @default.
• W2346104295 cites W2109674994 @default.
• W2346104295 cites W2122026938 @default.
• W2346104295 cites W2125131255 @default.
• W2346104295 cites W2132272732 @default.
• W2346104295 cites W2147263959 @default.
• W2346104295 cites W2163576489 @default.
• W2346104295 cites W2167151894 @default.
• W2346104295 cites W2216249120 @default.
• W2346104295 cites W2400023642 @default.
• W2346104295 cites W300178483 @default.
• W2346104295 cites W4302083976 @default.
• W2346104295 doi "https://doi.org/10.1007/s10585-016-9799-5" @default.
• W2346104295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27146156" @default.
• W2346104295 hasPublicationYear "2016" @default.
• W2346104295 type Work @default.
• W2346104295 sameAs 2346104295 @default.
• W2346104295 citedByCount "11" @default.
• W2346104295 countsByYear W23461042952017 @default.
• W2346104295 countsByYear W23461042952019 @default.
• W2346104295 countsByYear W23461042952020 @default.
• W2346104295 countsByYear W23461042952021 @default.
• W2346104295 countsByYear W23461042952022 @default.
• W2346104295 countsByYear W23461042952023 @default.
• W2346104295 crossrefType "journal-article" @default.
• W2346104295 hasAuthorship W2346104295A5016915382 @default.
• W2346104295 hasAuthorship W2346104295A5033272451 @default.
• W2346104295 hasAuthorship W2346104295A5060968852 @default.
• W2346104295 hasAuthorship W2346104295A5079339358 @default.
• W2346104295 hasAuthorship W2346104295A5087962688 @default.
• W2346104295 hasAuthorship W2346104295A5091444297 @default.
• W2346104295 hasBestOaLocation W23461042952 @default.
• W2346104295 hasConcept C121608353 @default.
• W2346104295 hasConcept C126322002 @default.
• W2346104295 hasConcept C143998085 @default.
• W2346104295 hasConcept C2775930923 @default.
• W2346104295 hasConcept C2776694085 @default.
• W2346104295 hasConcept C2777292972 @default.
• W2346104295 hasConcept C2778119113 @default.
• W2346104295 hasConcept C2780147359 @default.
• W2346104295 hasConcept C502942594 @default.
• W2346104295 hasConcept C530470458 @default.
• W2346104295 hasConcept C71924100 @default.
• W2346104295 hasConcept C98274493 @default.
• W2346104295 hasConceptScore W2346104295C121608353 @default.
• W2346104295 hasConceptScore W2346104295C126322002 @default.
• W2346104295 hasConceptScore W2346104295C143998085 @default.
• W2346104295 hasConceptScore W2346104295C2775930923 @default.
• W2346104295 hasConceptScore W2346104295C2776694085 @default.

• next